Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study
Authors
Keywords
-
Journal
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Volume -, Issue -, Pages jnnp-2021-328568
Publisher
BMJ
Online
2022-06-02
DOI
10.1136/jnnp-2021-328568
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis
- (2022) Ingrid Anne Lie et al. EUROPEAN RADIOLOGY
- Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
- (2022) Pascal Benkert et al. LANCET NEUROLOGY
- MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a
- (2021) Maria P. Sormani et al. Multiple Sclerosis and Related Disorders
- Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance
- (2021) Charidimos Tsagkas et al. HUMAN BRAIN MAPPING
- Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis
- (2021) Kristin Wesnes et al. Multiple Sclerosis and Related Disorders
- The potential of serum neurofilament as biomarker for multiple sclerosis
- (2021) Stefan Bittner et al. BRAIN
- Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis
- (2021) Claire Bridel et al. NEUROLOGY
- Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis
- (2020) Barbora Srpova et al. Multiple Sclerosis Journal
- Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis
- (2020) Mattia Rosso et al. Annals of Clinical and Translational Neurology
- Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
- (2020) Simon Thebault et al. Scientific Reports
- Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years
- (2019) Ester Cantó et al. JAMA Neurology
- Serum neurofilament light chain levels associations with gray matter pathology: a 5‐year longitudinal study
- (2019) Dejan Jakimovski et al. Annals of Clinical and Translational Neurology
- Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
- (2018) Christian Barro et al. BRAIN
- Are neurofilaments valuable biomarkers for long-term disease prognostication in MS?
- (2018) Michael Khalil Multiple Sclerosis Journal
- Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
- (2018) Tanuja Chitnis et al. Annals of Clinical and Translational Neurology
- Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
- (2016) Jens Kuhle et al. Multiple Sclerosis Journal
- Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
- (2016) Jens Kuhle et al. Multiple Sclerosis Journal
- Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant
- (2015) Martijn D. Steenwijk et al. BRAIN
- Corticospinal tract integrity is related to primary motor cortex thinning in relapsing–remitting multiple sclerosis
- (2015) Niels Bergsland et al. Multiple Sclerosis Journal
- Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis?
- (2015) B. Bielekova et al. NEUROLOGY
- Corticospinal tract integrity is related to primary motor cortex thinning in relapsing–remitting multiple sclerosis
- (2015) Niels Bergsland et al. Multiple Sclerosis Journal
- Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis
- (2014) Sandra Meyer-Moock et al. BMC Neurology
- Body fluid biomarkers in multiple sclerosis
- (2013) Manuel Comabella et al. LANCET NEUROLOGY
- Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
- (2013) Angela Vidal-Jordana et al. Multiple Sclerosis Journal
- ω-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study)
- (2012) Øivind Torkildsen et al. ARCHIVES OF NEUROLOGY
- Neurofilaments as biomarkers in multiple sclerosis
- (2012) Charlotte E Teunissen et al. Multiple Sclerosis Journal
- An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis
- (2011) Paul Schmidt et al. NEUROIMAGE
- Connecting white matter injury and thalamic atrophy in clinically isolated syndromes
- (2009) Roland G. Henry et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Mapping the human brain white matter tracts relative to cortical and deep gray matter using diffusion tensor imaging at high spatial resolution
- (2009) Khader M. Hasan et al. MAGNETIC RESONANCE IMAGING
- Measures in the first year of therapy predict the response to interferon β in MS
- (2009) J Río et al. Multiple Sclerosis Journal
- A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes
- (2008) Antonia Ceccarelli et al. NEUROIMAGE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started